Orphan Drug Opportunity Graphium’s VBX-100 glycosylated THC has FDA Orphan Drug Designation for pediatric ulcerative colitis, signaling a potential fast-track development narrative and interest from specialty pharma partners seeking orphan indications in gastroenterology.

Inflammation Focus With a proprietary glycosylation platform aimed at reducing gastrointestinal inflammation, target opportunities exist with biotech and pharma companies pursuing inflammatory bowel disease therapies, pediatric GI care, and endocannabinoid system modulation.

Funding Readiness Recent financing milestones and ongoing fundraising signals appetite from investors and potential co-development or licensing partners who can supply capital for remaining animal studies and Phase I/II clinical programs.

Strategic Collaboration Malachite and Graphium’s structure as a public company subsidiary creates avenues for strategic partnerships, licensing of glycosylated cannabinoid tech, and joint ventures with firms seeking novel GI inflammation treatments.

Market Positioning Significant market size of inflammatory bowel disease combined with a non-psychoactive cannabinoid approach offers differentiation; explore opportunities with contract research organizations, contract manufacturers, and specialty distributors focused on GI and pediatric therapeutics.